Research programme: anti-fibrotic therapeutics - Macomics
Latest Information Update: 26 Sep 2025
At a glance
- Originator Macomics
- Class Antifibrotics; Monoclonal antibodies
- Mechanism of Action Macrophage modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Fibrosis
Most Recent Events
- 25 Jul 2025 Early research in Fibrosis in United Kingdom (Parenteral)(Macomics pipeline, July 2025)